Debra Frye Selected Research

taxane

2/2002

Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Debra Frye Research Topics

Disease

4	Breast Neoplasms (Breast Cancer) 09/2005 - 01/2002
2	Neoplasms (Cancer) 09/2005 - 02/2002
1	Pathologic Complete Response 09/2005
1	Febrile Neutropenia 01/2003

Drug/Important Bio-Agent (IBA)

2	Fluorouracil (Carac)FDA LinkGeneric 09/2005 - 02/2002
1	Paclitaxel (Taxol)FDA LinkGeneric 09/2005
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2005
1	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2005
1	Estrogens (Estrogen)FDA Link 08/2004
1	Tamoxifen FDA LinkGeneric 08/2004
1	Estrogen ReceptorsIBA 08/2004
1	eniluracilIBA 02/2002
1	taxaneIBA 02/2002
1	AnthracyclinesIBA 02/2002
1	Docetaxel (Taxotere)FDA Link 01/2002
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2002
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2002

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 09/2005 - 01/2003
1	Therapeutics 01/2003